| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| GlaxoSmithKline has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Cancer Therapies | 23 |
$500 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Medical & Dental Adhesives & Sealants | 22 |
$500 |
| 29-Nov-2009 | Freedonia Group Inc, The | The Freedonia Group | Freedonia Focus on Weight Loss Products & Services | 24 |
$500 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 23-Nov-2009 | Reuters Investment Profile |
N/A
| GlaxoSmithKline PLC: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. | 12 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Engineering & Research Industry Trends, Statistics & Analysis 2009 (Summary) | 70 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Engineering & Research Industry Market Research and Competitive Analysis 2009 | 729 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Health Care Industry Market Research and Competitive Analysis 2010 | 730 |
$299 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Plunkett's Health Care Technologies Overview 2010 (Summary) | 80 |
$199 |
0.29% Nasdaq 
Research Reports
